Biostock: Investor Pitch: Spermosens

Se intervjun på biostock.se:

https://www.biostock.se/2024/04/biostock-investor-pitch-spermosens-2/

Detta är ett pressmeddelande från BioStock – Connecting Innovation & Capital. https://www.biostock.se

11 April, 2024

Press releases

Spermosens concludes clinical study with statistically significant results supporting the diagnostic value of JUNO-Checked

11-06-2025 Regulatory

Spermosens AB (“Spermosens” or the “Company”) today announces positive topline results from its clinical study conducted at the Reproductive Medicine Center (RMC) in Malmö. The study was designed to validate the diagnostic value of the Company’s patented JUNO-Checked system and has now reached a successful conclusion. The results demonstrate a statistically significant correlation between the JUNO Score, a measurement of sperm binding to the JUNO receptor, and fertilization rate in IVF.

The capital raise and issue announced in March 2025 is approved by Inspectorate of Strategic Products

05-06-2025 Regulatory

On March 4, 2025 Spermosens announced that the company has secured a SEK 10.8 million strategic investment through a directed issue. The investment is fulfilling the capital need until mid-2026. At the same time, Spermosens assessed that the issue had to be notified according to the Act (2023:560) on the review of foreign direct investments. A notification was sent to the Inspectorate of Strategic Products. After review, the authority today informed Spermosens that it leaves the notification without further action, which basically is the same as approving the issue.

Last day of trading in warrants series TO 5 in Spermosens is 12 June 2025

05-06-2025 Regulatory

12 June 2025 is the last day of trading in warrants of series TO 5 in Spermosens AB (publ) (“Spermosens” or the “Company”). Subscription of shares by exercise of warrants of series TO 5 is ongoing until 16 June 2025. One (1) warrant of series TO 5 entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 0.0055.

The subscription price for warrants of series TO 5 has been determined – the exercise period begins today

02-06-2025 Regulatory

During the fourth quarter of 2024, Spermosens AB (publ) (“Spermosens” or the “Company”) carried out a rights issue of units with preferential rights for existing shareholders, as well as directed issues of units to a number of external investors, existing shareholders, and members of the Company’s Board and management. Both the rights issue and the directed issues included units consisting of shares, warrants of series TO 5, and warrants of series TO 6. In connection with the directed issues, the Company also secured a credit facility under which the lender received warrants of series TO 5 and TO 6 free of charge. The exercise period for the warrants of series TO 5 (the “Warrants”) begins today on 2 June 2025 and runs until 16 June 2025. One (1) Warrant entitles the holder to subscribe for one (1) new share in Spermosens at a subscription price of SEK 0.0055 per share. Upon full exercise of all 467,740,274 Warrants, the Company will receive approximately SEK 2.6 million before transaction costs. To avoid the Warrants expiring without value, holders must exercise them no later than 16 June 2025. Please note that certain nominees (e.g. banks) may require a response from their clients prior to this deadline. Warrant holders are therefore encouraged to contact their respective nominees (e.g. banks) well in advance of the last day in the exercise period.

Spermosens publishes annual report for the financial year 2024

26-05-2025 Regulatory

Spermosens hereby announces that the annual report for 2024 is now available for download on the company’s website, www.spermosens.com. The annual report is also attached as a PDF to this press release. Please note that this version is an English translation of the official Swedish annual report (Årsredovisning) and has not been audited. As previously announced, the Annual General Meeting will be held on 16 June 2025.